Abstract : The therapeutic effect found histologically after surgery following neoadjuvant chemotherapy NAC correlates with patient prognosis. Such correlations must consider the remaining invasive lesions as well as intra-ductal components and lymph node metastasis. To this end, we compared the residual cancer burden RCB index with the conventional method of judging the histopathological therapeutic effect. We also took into account the clinicopathological features of patients related to recurrence and prognosis by the RCB index. We studied 244 cases of primary breast cancer in 238 patients who had undergone surgery after NAC in Showa University Hospital from 2005 to 2014. We classi ed the cases into groups based on the Japanese Breast Cancer Society s criteria for evaluating the histological therapeutic effect and the RCB index. The cases were also analyzed in regard to various clinicopathological factors. The prognosis was evaluated by drawing recurrence-free survival curves using the Kaplan-Meier method, and the log rank test was used to test statistical significance. The RCB index was evaluated for cases of Grade 0-1b that had a certain degree of residual tumor tissue. Comparison of the recurrence-free survival rates in each of the RCB index groups indicated a signi cant correlation, although only for patients with some degree of residual malignancy even after chemotherapy. We conclude that the RCB index can be used for providing a more precise prediction of recurrence.
undergo surgery following neoadjuvant chemotherapy NAC or have surgery first and then receive chemotherapy [1] [2] [3] . Also, the histological therapeutic effect seen in surgical specimens following NAC correlates with patient prognosis, with long-term survival achieved particularly in patients diagnosed as having achieved a pathological complete response pCR 2 4 . A metaanalysis of 12 recent clinical studies of NAC for breast cancer reported that pCR can serve as a surrogate endpoint for event-free survival EFS and / or overall survival OS 5 . In general, the most commonly used criteria for histological evaluation are the diagnostic criteria of Fisher et al 4 used in the NSABP B-18 study ; however, that study assumed that no invasive lesions remained, and intra-ductal components and lymph node metastasis were not taken into account. The later NSABP B-27 study evaluated intraductal components in addition to the diagnostic criteria of Fisher et al 6 . In addition, a recent report recommended that the residual presence of lymph node metastases should also be evaluated 5 . We therefore consider that the histological evaluation criteria used in such cases need to be clarified, of course taking into account the objectivity and reproducibility of histological evaluations. The residual cancer burden RCB index proposed by Symmans et al 7 has been used in numerous large-scale clinical studies, including I-SPY 1, 2 , GEICAM, ACOSOG Z11103 , CALGB 40601, 40603 , NSABP B-40, B-41 , and ABCSG 3, 4 , and its reproducibility has been evaluated 8 . Based on this background, we compared the RCB index with the conventional method of judging the histopathological therapeutic effect, that is, by evaluating the status of residual invasive lesions. We also investigated the significance of clinicopathological features and recurrence for prognosis by the RCB index.
Materials and methods

Methods
The subjects of this study were 244 cases of primary breast cancer in 238 patients who had undergone surgery after NAC in Showa University Hospital from 2005 to 2014. All the subjects were women, and 6 patients had bilateral synchronous breast cancer.
We collected the clinical and pathological information about the study subjects into a database, and then performed a retrospective survey of the medical records regarding postoperative recurrence and death. We classified the cases into two groups Grade 0, 1a, 1b, 2a and Grade 2b, 3 based on the Japanese Breast Cancer Society s criteria for evaluating the histological therapeutic effect. We also classified them into two groups RCB-0, 1 and RCB-2, 3 after calculating the RCB index for each case. The cases were analyzed in regard to various clinicopathological factors including age, clinical stage, histological type, vascular invasion, lymph node metastasis, biomarkers, chemotherapy regimen, surgical procedure, recurrence, and death, and analyzed using the t-test and chi-square test. Prognosis was evaluated by drawing recurrence-free survival curves using the Kaplan-Meier method, and the log rank test was used to test for statistical significance.
The biomarker findings were classified as follows : ≥ 10 ER•PgR was defined as positive, for HER2 only score 3 was considered positive, and ≥ 30 Ki67 was defined as positive.
Japanese Breast Cancer Society s criteria
These criteria classify cases into Grade 0 to Grade 3 based on the histological therapeutic effect. Details are described in Table 6 9 .
RCB index
The extent of residual disease RD in the post-treatment surgical resection specimen could be determined from the bi-dimensional diameters of the primary tumor bed in the resection specimen d 1 and d 2 , the proportion of the primary tumor bed that contains invasive carcinoma f inv , the number of axillary lymph nodes containing metastatic carcinoma LN , and the diameter of the largest metastasis in an axillary lymph node d met . If multiple tumors were present, the dimensions of the largest tumor were recorded. Bi-dimensional measurements of the primary tumor bed millimeters were combined as follows :
The proportion of invasive carcinoma f inv within the cross sectional area of the primary tumor bed was estimated from the overall percent area of carcinoma CA , and then corrected for the component of in situ carcinoma CIS :
From the above, we defined the RCB index as follows : They identified two cutoff points to assign patients with RD not RCB-0 after NAC into one of three classes : RCB-1 minimal RD , RCB-2 moderate RD , and RCB-3 extensive RD . Two cutoff points were determined sequentially by maximizing the profile log-likelihood of a multivariate Cox model that included the clinical covariates and the dichotomized RCB index. The first cutoff point RCB-3 and RCB-1 / 2 was selected as the 87th percentile RCB, 3.28 , and the second RCB-1 and RCB-2 corresponds to the 40th percentile RCB, 1.36 7 .
Results
Data on patient background characteristics for the 244 cases are compiled in Table 1 . The mean patient age was 51.6 years, and the mean duration of follow-up was 30.5 6-120 months. Recurrence was seen in 38 cases, and 11 cases died. The mean time from surgery until recurrence was 28.2 months, and the mean time until death was 46.1 months.
No striking differences were found in the distributions of the disease stage in each group based on the pretreatment stage, using the defined criteria for evaluating the histological therapeutic effect according to the General Rules for Clinical and Pathological Recording of Breast Cancer or when using the RCB index Table 2 . Table 3 details the clinicopathological factors for each of the histological therapeutic effect evaluation criteria of the General Rules for Clinical and Pathological Recording of Breast Cancer. There was a tendency for the diameter of invasive tumor and the degree of vascular invasion and lymph node metastasis to increase as the percentage of residual invasive lesions increased. Stratification of the biomarker findings indicated that, compared with the overall distributions, the group diagnosed with Grade 0, 1a, 1b, 2a showed a tendency for more ER , HER2 , ki67 30 cases, while the Grade 2a, 3 group showed a tendency for more ER , HER2 and ER , HER2 , ki67 ≥ 30 cases. In addition, the rates of recurrence and death were low for the Grade 2b, 3 cases, at 7.7 and 0.0 , whereas the rates were 17.7 and 5.8 , respectively, in the Grade 0, 1a, 1b, 2a group of patients ; however, these differences were not significant. Table 4 represents the stratification of clinicopathological factors for each RCB index group. Stratification of the biomarker findings indicated that, compared with the overall distributions, RCB-0, 1 showed a tendency for more cases of ER , HER2 , while RCB-2, 3 showed a tendency for more cases of ER , HER2 , ki67 30 . In addition, there were no significant differences between the groups for rates of recurrence and death. Analysis of the recurrence-free survival plots is represented in Fig. 3 , with the graph on the left showing the Grade 0, 1a, 1b, 2a and Grade 2a, 3 groups based on the histological therapeutic effect evaluation criteria of the Japanese Breast Cancer Society. The right plot shows the curves Fig. 3 . Recurrence-free survival RFS analysis The left graph represents the analysis for the Grade 0, 1a, 1b, 2a and Grade 2b, 3 groups based on the histological therapeutic effect evaluation criteria of the Japanese Breast Cancer Society. The right graph represents the analysis for the RCB-0, 1 and RCB-2, 3 groups based on the RCB index. The recurrence-free survival plots were compared, but the analyses revealed no statistically significant differences P 0.1236 and P 0.0645 . for the RCB-0, 1 and RCB-2, 3 groups based on the RCB index. Analyses of these recurrencefree survival plots revealed no statistically significant differences P 0.1236 and P 0.0645 . Table 5 presents the stratification of clinicopathological factors for each RCB index group for cases of Grade 0-1b that had a certain degree of residual tumor tissue, after excluding the cases of pCR and near pCR, which are considered to have a good prognosis. Stratification of the biomarker findings indicated that the percentage of ER , HER2 , ki67 30 cases tended to increase as the RCB index increased, whereas, conversely, the percentage of ER , HER2 , ki67 30 cases tended to decrease. There were no significant differences between the groups for rates of recurrence and death.
Analysis of the recurrence-free survival plots for cases of Grade 0 -1b that had a certain degree of residual tumor tissue Fig. 4 was performed for the RCB-1 and RCB-2, 3 groups based on the RCB index for cases of Grade 0 -1b. Comparison of the recurrence-free survival rates in each of the RCB index groups indicated a significant correlation P 0.0483 . These results indicate that RCB index can be used to predict outcomes. In addition, it seems that we can treat the cases of RCB-1 group almost equally to RCB-0 pCR cases.
Discussion
In this study, we used the RCB index as a means for evaluating the status of residual tumors and investigated the histological therapeutic effect based on criteria of the General Rules for Clinical and Pathological Recording of Breast Cancer, the clinical histopathological data, recurrence, and prognosis.
Reports to date have identified various prognostic factors in patients undergoing surgery following NAC. Those factors include the clinical stage, histological type, tumor diameter, axillary lymph node metastasis, vascular invasion, multifocal pattern of residual tumor, tumor necrosis, hormone receptors, positive rate of HER2, ki67 cells, menopausal status, and race AfricanAmerican [10] [11] [12] [13] [14] [15] . With respect to hormone receptors and positive rate of HER2, ki67 cells, our study supported these past reports. Concretely, the cases that had better effects of NAC showed a tendency for more cases in which estrogen receptor was negative, HER2 was positive, and ki-67 was high. In addition, most of these previous reports rated the tumor diameter and axillary lymph node metastasis as the most important prognostic factors [10] [11] [12] [13] , while a more recent study stated that it is better to use T0 N0 or T0 / is N0 as the definition of pCR 5 . In our present paper, we used the RCB index, which not only considers the primary lesion and axillary lymph node metastasis, but also might represent a more accurate prognostic index since it is a numerical rating. Table 6 shows the other criteria used for evaluating the histological therapeutic effect 16 .
The RCB index that we used herein has been employed in numerous clinical studies 8 . In addition, the reproducibility of the RCB index has been evaluated as high, with an RCB category concordance rate of 0.989 8 . One report stated that the following are important items that should be included in pathology reports: pCR / non-pCR, the T stage, N stage, and RCB index if not available, 2 perpendicular diameters of the tumor 17 .
Our present results found a significant correlation between the RCB index and the recurrencefree survival period, although only for patients with some degree of residual malignancy even after chemotherapy. We therefore conclude that the RCB index can be used to elicit a more precise prediction of recurrence. However, the RCB index did not show a significant correlation with for which chemotherapy is indicated, it is difficult to claim that a mean follow-up period of 30.5 months is even close to being sufficient. Thus, the issue of the duration of follow-up warrants further investigation.
